Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MRNS Marinus Pharmaceuticals Inc

-0.0297 (-1.99%)
Jun 13 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 409,479
Bid Price 1.46
Ask Price 1.60
News -
Day High 1.52


52 Week Range


Day Low 1.45
Company Name Stock Ticker Symbol Market Type
Marinus Pharmaceuticals Inc MRNS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0297 -1.99% 1.4603 18:09:02
Open Price Low Price High Price Close Price Prev Close
1.50 1.45 1.52 1.46 1.49
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,148 409,479 $ 1.47 $ 603,720 - 1.11 - 11.26
Last Trade Time Type Quantity Stock Price Currency
19:06:42 50 $ 1.46 USD

Marinus Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
79.78M 54.64M - 30.99M -141.41M -2.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Marinus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MRNS Message Board. Create One! See More Posts on MRNS Message Board See More Message Board Posts

Historical MRNS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.551.6351.451.52586,722-0.0897-5.79%
1 Month1.361.6351.271.421,030,0190.10037.37%
3 Months9.079.411.111.852,230,271-7.61-83.90%
6 Months8.5811.261.113.341,277,381-7.12-82.98%
1 Year10.6711.261.114.98959,564-9.21-86.31%
3 Years18.8019.831.116.28559,857-17.34-92.23%
5 Years3.8420.040.774.431,040,229-2.38-61.97%

Marinus Pharmaceuticals Description

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Your Recent History

Delayed Upgrade Clock